Key facts

  • A world lead within diabetes and haemophilia
  • Sales totalled DKK 78 billion in 2012 (EUR 10.5 billion)
  • In 2012 total insulin market share of 49% and modern insulin market share 46%, measured by volume (Source IMS)
  • 34.286 full time employees at the end of 2012
  • Focus on core areas with large unmet medical needs: Diabetes care, haemophilia, growth hormone disorders and other biopharmaceuticals
  • Strong global commercial and manufacturing setup
  • Listed on NASDAQ OMX Copenhagen and New York Exchanges